Objective-Antenatal screening for syphilis is well established in the United Kingdom. The prevalence of syphilis is now very low, prompting the question as to whether this screening programme is still necessary. This paper aims at identifying possible screening strategy options for the programme and comparing their eVectiveness and cost eVectiveness. Methods-The cost of the screening programme in the United Kingdom was estimated. This was based on the cost of screening tests, treatment, and follow up of infected women and their infants. This information was obtained from laboratories, antenatal clinics, and genitourinary medicine clinics. Epidemiological data from a survey of women treated for syphilis in pregnancy were analysed to identify groups at increased risk of syphilis. Strategic options for the screening programme were then identified. The eVectiveness, number needed to treat, and cost eVectiveness of these options were compared. Results-Antenatal screening in the United Kingdom detected at least 40 pregnant women who need treatment for syphilis every year. This means that 18 602 women are screened for every woman detected who needs treatment for syphilis. The marginal annual cost of this screening programme in the United Kingdom is £672 366. This is equivalent to 90p per woman screened, or £16 670 to detect one woman who needs treatment for syphilis. The screening programme could be targeted geographically at pregnant women in the Thames regions. This option has the potential to save £482 185. Other strategic options are to target pregnant women in non-white ethnic groups, or those born outside the United Kingdom. These targeted options would each detect between 70% and 77% of women needing treatment for syphilis. These options could potentially save £592 938 and £562 691 respectively. Conclusions-Targeting or stopping the screening programme would save relatively little money. Although selectively screening groups by country of birth or by ethnic group could detect at least 70% of cases, this would be politically and practically diYcult. Targeting by region would also be eVective, but would pose similar ethical and medicolegal problems. These facts and the changing international epidemiology of syphilis lead us to recommend that the current universal antenatal screening for syphilis should continue. (J Med Screen 2000;7:7-13) 
Antenatal screening for syphilis aims primarily at detecting pregnant women with congenitally transmissible syphilis (includes primary, secondary, or early latent syphilis), so that they can be treated with antibiotics to prevent transmission of infection. 1 This is beneficial because congenital syphilis results in stillbirths, premature births, neonatal deaths, and severe illness in infancy and beyond. [2] [3] [4] Screening and maternal treatment also stop the disease in infected women progressing to tertiary syphilis and being transmitted to their sexual partners.
While there have been no randomised controlled trials to evaluate antenatal syphilis screening, intervention studies have shown that screening pregnant women for syphilis eVectively reduces adverse outcomes such as stillbirths and early infant deaths. 3 Economic analyses carried out in Norway, England, and Thailand have consistently found that the benefits of antenatal syphilis screening outweigh its costs, even where the prevalence of maternal infection is low. [5] [6] [7] Stray-Pedersen's Norwegian study found that antenatal screening for syphilis would be cost beneficial at prevalences as low as five per 100 000 pregnancies. Another cost-benefit analysis conducted in East Anglia found that antenatal screening for syphilis was cost beneficial at an incidence of between one and 11 per 100 000 pregnancies. 8 There are over 750 000 births each year in the United Kingdom, and screening for syphilis has been a routine part of antenatal care. 9 The low level of infectious syphilis in the United Kingdom in the early 1990s prompted obstetricians, microbiologists, and general practitioners to ask whether we still need to screen pregnant women for this infection. [10] [11] [12] Some suggested that a targeted screening programme might be more cost eVective than the current policy of universal screening. 12 These concerns were reflected in a survey of health authorities and obstetric centres. 9 This survey found that a number of these were considering stopping or were reviewing their policies on antenatal syphilis screening.
These arguments form part of a wider debate on assessing the evidence for screening programmes in the United Kingdom. This has led to the formation of the National Screening Committee, which aims at assessing the evidence for existing and new screening programmes. The value of antenatal screening for syphilis has been particularly questioned following Health Service guidance on antenatal hepatitis B and HIV screening.
There has been a policy vacuum on antenatal syphilis screening in the United Kingdom, as the only national recommendations to screen pregnant women for syphilis originated from the Public Health Laboratory Service (PHLS) 10 years ago. 13 In order to inform the development of evidence based policy, the PHLS (its Syphilis Working Group and Communicable Disease Surveillance Centre (CDSC)) and the British Cooperative Clinical Group (BCCG) of genitourinary medicine (GUM) physicians conducted a survey of women treated in pregnancy for syphilis. 14 This was necessary because routine surveillance data from GUM clinics did not include information on pregnancy, and laboratory surveillance data were largely lacking at that time. 15 This paper uses epidemiological and economic data to determine the best strategic option for antenatal syphilis screening in the United Kingdom. The epidemiological data from the PHLS/BCCG survey were analysed to identify possible screening strategy options based on groups at risk of infection. 14 The costs of the screening programme were estimated so that the eVectiveness and cost eVectiveness of the strategic options could be compared.
Methods
There is a well established antenatal care infrastructure in place in the United Kingdom. Serological screening for syphilis is performed early in antenatal care, and testing is conducted on serum specimens that may also be tested for Rh and red cell antibodies, antibodies to rubella, HIV, 16 and hepatitis B 17 infections. Screening tests may be carried out in PHLS, Blood Transfusion Service, or NHS laboratories. Further confirmatory and refer-ence testing should then be carried out at a PHLS reference laboratory that also provides surveillance data. 18 Women with serological results indicative of syphilis infection may then be referred to a GUM physician.
COSTS OF THE ANTENATAL SYPHILIS SCREENING

PROGRAMME IN THE UNITED KINGDOM
The cost of the antenatal screening programme for syphilis in the United Kingdom was calculated based on three components: (1) The laboratory costs of conducting screening and confirmatory tests. (2) Antenatal clinic and GUM clinic costs of investigating and treating women with syphilis. (3) The cost of investigating infants born to women detected by screening. Data on laboratory costs were obtained by sending a questionnaire to 12 screening laboratories based in NHS trusts, the Blood Transfusion Service, and the PHLS. The sample included the main testing centres for antenatal syphilis screening. The 12 laboratories were selected after discussions with members of the PHLS syphilis subcommittee. Laboratories in the Blood Transfusion Service and PHLS that conduct large numbers of antenatal syphilis screening tests were selected. NHS laboratories were selected in London, where many trusts conduct their own antenatal screening tests.
Laboratories were asked to provide details of reagents, administration, capital, and overhead costs. The costs of these components varied between laboratories, and outlying costs in small volume laboratories were excluded from the analysis (table 1) Women with serological results indicative of syphilis infection should always be referred to a GUM physician for assessment. 18 Estimates of GUM clinic, antenatal clinic, and paediatric clinic costs were obtained from hospitals within a London health authority. The cost of a maternity outpatient attendance was based on the average price in a contract portfolio in 1996 to 1997. The cost of GUM clinic treatment was based on the average cost in 1997 of attending a clinic to receive a 10 to 21 day course of penicillin injections. 19 This reflects variation in current clinical practice in the United Kingdom.
The costs of following up the infants of women detected through screening were based on the cost of performing four serology tests at one, two, three, and six months of age, 20 and of four paediatric outpatient visits.
The analysis was based on a range of assumptions listed in box 1. A sensitivity analysis was conducted to assess the eVects of various assumptions made in the analysis.
SCREENING STRATEGY OPTIONS
The survey of GUM physicians reported that 139 women were treated for syphilis during, or within, three months of pregnancy. 14 This total and the estimated prevalence of 0.06 per 1000 live births are minimum estimates of the impact of syphilis on pregnancy in the United Kingdom. This is because the survey response rate was only 70 to 80%, and it could not include women who were treated by obstetricians instead of being referred to GUM clinics. 21 The antenatal screening programme detected 121 of the 139 women. Three possible strategic options for antenatal syphilis screening in the United Kingdom were examined: (1) To continue the current universal screening programme.
(2) To target the screening programme to pregnant women in high risk groups. (3) To stop the screening programme entirely.
The eVectiveness or "number needed to treat" of the strategies was compared. This included the number of women who need to be screened to detect one infected woman or to prevent one case of congenital syphilis. The proportion of all cases that would be detected by each targeted screening strategy was also calculated.
The cost eVectiveness of the strategies was also compared. This analysis included the cost per infected woman detected and the cost per congenital syphilis detected. The cost per pregnancy screened was also calculated.
The analysis also compared the incremental cost eVectiveness of screening all pregnant women with targeting screening to certain groups at higher risk of infection.
Results
COSTS OF THE ANTENATAL SYPHILIS SCREENING
PROGRAMME IN THE UNITED KINGDOM
The cost of conducting screening tests was estimated from data provided by eight laboratories. These laboratories performed a total of 169 140 antenatal screening tests for syphilis in one year, approximately one fifth of the number of antenatal tests conducted in the United Kingdom.
The cost components for laboratory screening are described in table 1. The average cost of reagents was 16p (range 9p to 44p) per test. The average cost of labour was 53p (8p to £2.41) per test. The average marginal cost of a screening test, based on reagents and labour alone, was 69p (17p to £2.85).
The average overhead costs, including administration, other staYng, and capital costs, were £2.80 (£2.16 to £3.80) per test. When these overheads were included, the total cost of a screening test became £3.49 (£2.33 to £6.65). It was assumed that these large overhead costs would not be recoverable from fully employed laboratories. This report is concerned with the savings that may result from targeting or stopping screening. Because of this, the main analysis is based on the marginal costs of testing and does not include laboratory overheads.
Cost details for confirmatory testing were provided by four PHLS and NHS laboratories ( The cost of treating and following up women detected by screening was based on the cost of one antenatal clinic attendance followed by a course of treatment at a GUM clinic (table 2) . The cost of this was estimated to be £936.20 (£519 to £1364). The cost of following up infants born to women detected by screening was based on serological testing and the cost of four paediatric outpatient attendances, and was estimated to be £283.56 (£209.32 to £350.60).
These cost components were used to estimate the total marginal costs of antenatal screening for the United Kingdom (table 3) . This was estimated to be £672 366 (£161 849 to £2 306 382), equivalent to 90p per pregnancy screened. This analysis was based on direct NHS costs and did not include any indirect costs to pregnant women such as anxiety or time taken to attend the clinics. The analysis also excluded partner notification and treatment costs for the women's sexual partners.
A sensitivity analysis was performed to examine the most important influences on the cost eVectiveness of the screening programme. This was based on the marginal cost per congenital case prevented (table 4). This found that varying the cost of the screening test had the greatest eVect on the overall cost eVectiveness of screening. This was because of the wide diVerences in laboratory costs and practice, and the large number of tests performed. Changing the vertical transmission rate had less eVect on the cost eVectiveness because only a small proportion of the overall cost of the programme was spent on following up the babies of infected women.
SCREENING STRATEGY OPTIONS
Analysis of the PHLS/BCCG surveillance data identified three groups of pregnant women who had a higher risk of syphilis and who could be reasonably targeted in a restricted screening programme. 14 
Geographically targeting pregnant women in the Thames regions
The prevalence of syphilis requiring treatment among these women was estimated to be 0.18 per 1000 births (95% CI 0.15 to 0.22).
Selectively targeting pregnant women in non-white ethnic groups
The prevalence of syphilis requiring treatment among these women was estimated to be 0.62 per 1000 births (95% CI 0.50 to 0.75).
Selectively targeting pregnant women born outside the United Kingdom
The prevalence of syphilis requiring treatment among these women was estimated to be 0.42 per 1000 births (95% CI 0.34 to 0.50).
The prevalences of syphilis requiring treatment among pregnant women in these groups, compared with the overall prevalence observed, were eight times higher in the Thames regions, 34 times higher in non-white ethnic groups, and 28 times higher among women born outside the United Kingdom.
The analysis was based on pregnant women treated for syphilis who were detected by antenatal screening and reported in the PHLS/ BCCG survey. This does not include pregnant women treated for syphilis who were not detected by antenatal screening-for example, those detected first at GUM clinics. The analysis was based on a range of assumptions that are described in box 2. The eVectiveness and cost eVectiveness of the diVerent screening strategy options is compared in table 5. This analysis is based on a marginal cost of 90p per pregnant woman screened. The incremental cost eVectiveness of universal screening is compared with the targeted screening strategy options in table 6.
UNIVERSAL SCREENING OF PREGNANT WOMEN
Universal antenatal screening in the United Kingdom for three years was estimated to have detected a minimum of 121 pregnant women who required treatment for syphilis. Treating these women would prevent an estimated 40 cases of congenital syphilis and would stop 40 women progressing to tertiary syphilis. Based on these estimates, a maximum of 18 602 women would need to be screened to detect one woman who needed treatment for syphilis. A maximum of 55 713 women would need to be screened to prevent one case of congenital syphilis.
The marginal cost of universal screening was £672 366, the equivalent of £16 670 for each woman treated for syphilis, or £49 928 for each case of congenital syphilis prevented.
TARGETING PREGNANT WOMEN IN THE THAMES
REGIONS
If screening was restricted to pregnant women in the Thames regions (London and south east England), then at least 85 women requiring treatment for syphilis would be detected over three years, 70% of those detected by universal screening. Treating these women would prevent an estimated 27 cases of congenital syphilis, but would miss 13 of the cases (33%) prevented by universal screening. Approximately 28 women would be prevented from progressing to tertiary syphilis, but 12 cases of tertiary syphilis would be missed. A maximum of 6613 women would need to be screened to detect one woman requiring treatment, and 20 665 women would need to be screened to prevent one case of congenital syphilis. Targeting the screening programme to pregnant women in the Thames regions would cost £190 181. This is equivalent to £6712 to detect one woman requiring treatment, or £20 976 to prevent one case of congenital syphilis.
TARGETING PREGNANT WOMEN IN NON-WHITE ETHNIC GROUPS
Three years of targeting screening to pregnant women in non-white ethnic groups would have detected a minimum of 85 women requiring treatment, prevented 27 cases of congenital syphilis, and prevented 28 cases of tertiary syphilis. A maximum of 1907 women would need to be screened for each woman detected with syphilis, and 6092 women would need to be screened to prevent one case of congenital syphilis.
It would cost £79 428 to screen only pregnant women in non-white ethnic groups. This is equivalent to £2803 to detect one women requiring treatment, or £8958 to prevent one case of congenital syphilis.
TARGETING PREGNANT WOMEN BORN OUTSIDE THE UNITED KINGDOM
Targeting pregnant women born outside the United Kingdom over a three year period would have detected a minimum of 93 women requiring treatment, 77% of those detected by universal screening. Treating these women would have prevented an estimated 29 cases of congenital syphilis, and 31 cases of tertiary syphilis.
A maximum of 2791 women would need to be screened to detect one woman requiring treatment for syphilis, and 8828 women would need to be screened to prevent one case of congenital syphilis. Targeting women born outside the United Kingdom would cost £76 245, equivalent to £2460 to detect one woman requiring treatment, or £7780 to prevent one case of congenital syphilis.
If universal screening is compared with screening only in the Thames regions, the incremental cost per woman detected is £40 182, and per case of congenital syphilis prevented is £109 588 (table 6). If universal screening is compared with screening women in non-white ethnic groups, the incremental cost per woman detected is £49 412, and per congenital syphilis case prevented is £128 900. If universal screening is compared with screening women born outside the United Kingdom, the incremental cost per woman detected is 
Discussion
The annual marginal cost of the screening programme was estimated to be £661 176. This is equivalent to 90p per woman screened, or £16 393 to detect one woman requiring treatment.
The cost data for screening tests were obtained from a sample of laboratories that conduct a significant proportion of the antenatal syphilis screening tests in the United Kingdom. Although the marginal costs of the screening tests were relatively straightforward, laboratories used diVerent methods to calculate overheads. This, and the high overhead costs, meant that it was diYcult to extrapolate the total costs to the whole of the United Kingdom. Costs of clinical care for the mothers and infants were obtained from a small sample of clinics. While these might be less representative of the whole of the United Kingdom, they were only a small proportion of the overall costs.
There is good evidence that antenatal screening for syphilis is cost beneficial, 5-7 therefore this paper asks how screening should be conducted, either as a universal or targeted programme. There are three groups of pregnant women in the United Kingdom with high prevalences of syphilis who could be targeted for antenatal syphilis screening. These groups are pregnant women in the Thames regions, pregnant women in non-white ethnic groups, and pregnant women born outside the United Kingdom.
Targeting antenatal screening to women in the Thames regions, or to women of non-white ethnic groups, would detect approximately 70% of the cases of women requiring treatment for syphilis detected by the universal screening programme. Targeting women born outside the United Kingdom would be more eVective, detecting 77% of cases.
Targeting the relatively small group of pregnant women of non-white ethnic groups would be the cheapest option, costing £79 428. This would also be the most cost eVective option, costing £2803 for every woman detected who needed treatment. A larger screening programme would be needed to target pregnant women born outside the United Kingdom, costing £109 675, or £3538 to detect one woman requiring treatment. Targeting pregnant women in the Thames regions would cost £190 181, or £6712 for every woman detected who needed treatment.
The incremental cost eVectiveness analysis showed that while the universal screening option was more eVective than the targeted options, the cost per extra infected woman detected or congenital syphilis case prevented was much higher than in the targeted programmes. The incremental cost per woman detected ranged from £40 182 to £60 288, and per congenital syphilis case prevented ranged from £109 588 to £153 461 depending on which targeted programme was compared with the universal strategy. These results should be treated with caution as laboratories and clinics may find it administratively diYcult to move from universal to selective screening. This means that selectively screening population groups may not result in proportionately lower costs.
Targeted strategies have other inherent diYculties. It would be politically sensitive to change from screening all pregnant women to screening a few on the basis of ethnic group or country of birth. Even if this hurdle could be overcome, this kind of targeting is diYcult to implement and is likely to result in a poor uptake of tests. Experience from antenatal screening for hepatitis B and HIV suggests that targeted syphilis screening will not be successful. 22 23 Even if the more practical and acceptable option of targeting women in the Thames regions is chosen, problems would remain because up to 30% of cases would still be missed. There could be substantial medicolegal costs attached to failing to prevent miscarriages, stillbirths, and illness resulting from congenital infection because of missed cases of maternal syphilis. Certainly trusts and health authorities would be taking on financial risks if they did not provide routine screening.
Targeting the screening programme also runs the risk of missing newly developing risk groups and unexpected increases in transmission. The former include women who have direct or indirect sexual contact with Russia and Eastern Europe. This area is in the midst of a new syphilis epidemic that has already had an impact in the United Kingdom. 24 Policy must take into account how unpredictable syphilis is, and how diYcult it can be to control. This was illustrated by a recent (1997 to 1998) outbreak of indigenously acquired syphilis in Bristol that aVected over 40 people, including six pregnant women. 25 While a cost-benefit analysis is beyond the scope of this paper, a study conducted in 1996 in East Anglia did assess the financial benefits of treating an infected pregnancy. 8 These ranged from £8812 to £22 863 depending on the assumptions made. The least certain assumptions were based on the likelihood of congenital syphilis resulting in disability, as little modern data are available. The analysis did not include the benefits of preventing infected mothers or their sexual partners from progressing to tertiary syphilis. Applying the benefits from the East Anglia paper to the costs of the universal screening programme in this analysis, gives a cost:benefit ratio ranging from 1.89:1 to 0.73:1, depending on the assumptions made. The targeted screening options would be cost beneficial using these estimates.
The screening costs varied greatly between laboratories, from 17p to £4.51 per test (reagent plus labour costs, including outliers (table 1) ). The laboratories with larger throughputs tended to have lower unit costs and be more cost eVective. The importance of minimising laboratory costs has previously been recognised in economic analyses of antenatal hepatitis B screening in Canada 26 and the United Kingdom, 27 and of HIV screening. 28 The wide range of estimates of unit costs suggests scope for reducing overall costs and increasing cost eVectiveness. At the same time it would be essential to retain reference laboratory services. 18 In summary, stopping the screening programme would not save much money (under £1 per pregnancy). Targeted screening, either by locality or risk group (ethnic group or country of birth) would save even less money, would probably be ineVective, and might also be unacceptable. The analyses in this paper support continuing the current universal programme for antenatal syphilis screening, a conclusion to be supported by a Health Services Circular. 18 
